SOLUBLE CD150 ISOFORM LEVEL IN PLASMA OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

Area of Science:

• Immunology
• Hematology
• Molecular Biology

Background:

• SLAMF1/CD150 plays a role in B cell signaling in chronic lymphocytic leukemia (CLL).
• Signaling can occur via homophilic CD150 binding or interaction with the soluble CD150 isoform (sCD150).
• The role of plasma sCD150 in CLL cell activation is not fully understood.

Purpose of the Study:

• To develop an ELISA for sCD150 quantification.
• To assess sCD150 levels in CLL patient plasma.
• To correlate sCD150 levels with B cell CD150 expression.

Main Methods:

• Analysis of plasma and peripheral blood mononuclear cells from 40 CLL patients.
• Development and application of an ELISA assay for sCD150.
• Ex vivo drug sensitivity and cell viability assays were performed.

Main Results:

• sCD150 was detected in all CLL plasma samples at varying levels.
• Low B cell surface CD150 expression correlated with high plasma sCD150.
• Elevated plasma sCD150 was linked to increased sensitivity to chemotherapy.

Conclusions:

• CLL B cells actively secrete sCD150, leading to its accumulation in plasma.
• Plasma sCD150 may contribute to the clinical variability observed in CLL.
• sCD150 levels could serve as a predictive biomarker for treatment response.